Joanne Wuensch
Stock Analyst at Citigroup
(4.49)
# 158
Out of 4,810 analysts
371
Total ratings
62.45%
Success rate
11.85%
Average return
Main Sectors:
Stocks Rated by Joanne Wuensch
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| COO The Cooper Companies | Maintains: Buy | $115 → $110 | $78.76 | +39.66% | 20 | Mar 7, 2025 | |
| ABT Abbott Laboratories | Maintains: Buy | $135 → $160 | $127.96 | +25.04% | 20 | Mar 4, 2025 | |
| DXCM DexCom | Maintains: Buy | $101 → $104 | $67.39 | +54.33% | 13 | Mar 4, 2025 | |
| SGHT Sight Sciences | Maintains: Neutral | $4.6 → $3 | $2.41 | +24.48% | 10 | Mar 4, 2025 | |
| TNDM Tandem Diabetes Care | Downgrades: Neutral | $35 → $24 | $17.03 | +40.93% | 14 | Mar 4, 2025 | |
| MDT Medtronic | Upgrades: Buy | $92 → $107 | $84.22 | +27.05% | 19 | Mar 4, 2025 | |
| SYK Stryker | Reinstates: Buy | $450 | $353.42 | +27.33% | 13 | Feb 26, 2025 | |
| PODD Insulet | Maintains: Buy | $310 → $355 | $255.47 | +38.96% | 14 | Feb 21, 2025 | |
| GEHC GE HealthCare Technologies | Maintains: Buy | $103 → $110 | $64.39 | +70.83% | 3 | Feb 13, 2025 | |
| BSX Boston Scientific | Maintains: Buy | $107 → $122 | $94.27 | +29.42% | 34 | Feb 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $640 → $711 | $490.13 | +45.06% | 16 | Jan 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $200 → $245 | $270.27 | -9.35% | 24 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $185 → $175 | $154.36 | +13.37% | 12 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $130 → $145 | $117.97 | +22.91% | 4 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $81 → $83 | $69.87 | +18.79% | 19 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $37 → $35 | $28.38 | +23.33% | 20 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $17 → $7.5 | $5.41 | +38.63% | 10 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $24 → $22 | $12.25 | +79.59% | 4 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $132 → $162 | $92.91 | +74.36% | 20 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $16 → $22 | $16.73 | +31.50% | 14 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $45 → $50 | $31.32 | +59.64% | 6 | Oct 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $135 → $110 | $103.20 | +6.59% | 17 | Aug 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $94 → $85 | $59.42 | +43.05% | 7 | Aug 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $134 → $120 | $101.97 | +17.68% | 22 | Jul 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $220 → $250 | $205.71 | +21.53% | 5 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $67 → $69 | $90.58 | -23.82% | 5 | Nov 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $109 → $127 | $214.53 | -40.80% | 6 | Dec 10, 2018 |
The Cooper Companies
Mar 7, 2025
Maintains: Buy
Price Target: $115 → $110
Current: $78.76
Upside: +39.66%
Abbott Laboratories
Mar 4, 2025
Maintains: Buy
Price Target: $135 → $160
Current: $127.96
Upside: +25.04%
DexCom
Mar 4, 2025
Maintains: Buy
Price Target: $101 → $104
Current: $67.39
Upside: +54.33%
Sight Sciences
Mar 4, 2025
Maintains: Neutral
Price Target: $4.6 → $3
Current: $2.41
Upside: +24.48%
Tandem Diabetes Care
Mar 4, 2025
Downgrades: Neutral
Price Target: $35 → $24
Current: $17.03
Upside: +40.93%
Medtronic
Mar 4, 2025
Upgrades: Buy
Price Target: $92 → $107
Current: $84.22
Upside: +27.05%
Stryker
Feb 26, 2025
Reinstates: Buy
Price Target: $450
Current: $353.42
Upside: +27.33%
Insulet
Feb 21, 2025
Maintains: Buy
Price Target: $310 → $355
Current: $255.47
Upside: +38.96%
GE HealthCare Technologies
Feb 13, 2025
Maintains: Buy
Price Target: $103 → $110
Current: $64.39
Upside: +70.83%
Boston Scientific
Feb 6, 2025
Maintains: Buy
Price Target: $107 → $122
Current: $94.27
Upside: +29.42%
Jan 24, 2025
Maintains: Buy
Price Target: $640 → $711
Current: $490.13
Upside: +45.06%
Dec 11, 2024
Maintains: Neutral
Price Target: $200 → $245
Current: $270.27
Upside: -9.35%
Dec 11, 2024
Maintains: Buy
Price Target: $185 → $175
Current: $154.36
Upside: +13.37%
Dec 11, 2024
Maintains: Neutral
Price Target: $130 → $145
Current: $117.97
Upside: +22.91%
Dec 11, 2024
Maintains: Buy
Price Target: $81 → $83
Current: $69.87
Upside: +18.79%
Dec 11, 2024
Maintains: Neutral
Price Target: $37 → $35
Current: $28.38
Upside: +23.33%
Dec 11, 2024
Downgrades: Neutral
Price Target: $17 → $7.5
Current: $5.41
Upside: +38.63%
Dec 11, 2024
Downgrades: Neutral
Price Target: $24 → $22
Current: $12.25
Upside: +79.59%
Dec 11, 2024
Upgrades: Buy
Price Target: $132 → $162
Current: $92.91
Upside: +74.36%
Nov 5, 2024
Maintains: Sell
Price Target: $16 → $22
Current: $16.73
Upside: +31.50%
Oct 1, 2024
Maintains: Neutral
Price Target: $45 → $50
Current: $31.32
Upside: +59.64%
Aug 22, 2024
Maintains: Buy
Price Target: $135 → $110
Current: $103.20
Upside: +6.59%
Aug 22, 2024
Maintains: Neutral
Price Target: $94 → $85
Current: $59.42
Upside: +43.05%
Jul 10, 2024
Maintains: Neutral
Price Target: $134 → $120
Current: $101.97
Upside: +17.68%
Dec 12, 2022
Upgrades: Neutral
Price Target: $220 → $250
Current: $205.71
Upside: +21.53%
Nov 17, 2022
Maintains: Neutral
Price Target: $67 → $69
Current: $90.58
Upside: -23.82%
Dec 10, 2018
Upgrades: Outperform
Price Target: $109 → $127
Current: $214.53
Upside: -40.80%